Literature DB >> 28070831

The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.

Satoshi Tanaka1, Kanayo Suzuki1, Minoru Sakaguchi2.   

Abstract

BACKGROUND: Prolyl oligopeptidase (POP, EC 3.4.1.26) is a serine peptidase that hydrolyzes post-proline peptide bonds in peptides that are <30 amino acids in length. We previously reported that POP inhibition suppressed the growth of NB-1 human neuroblastomas cells and KATO III human gastric cancer cells. POP activity is commonly elevated in many cancers, which includes breast cancer. However, the effect of POP inhibition as a candidate breast cancer therapy is unknown.
METHODS: The effects of POP inhibition and knockdown on the proliferation of cultured human estrogen receptor-positive (ER+) MCF7 and T47D, and ER-negative (ER-) MDA-MB-231 breast cancer cell lines and the MCF12A non-tumorigenic epithelial cell line were tested by analyzing their influence on cell proliferation (WST-1 assay), cell viability (trypan blue exclusion assay), and cell cycle arrest (cell cycle analysis, cell cycle regulator proteins expression).
RESULTS: POP-specific inhibitors 3-({4-[2-(E)-styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thiopropyl-thioprolinal and RNAi-mediated POP knockdown inhibited the proliferation of MCF7 cells without inducing cell death. SUAM-14746-induced growth inhibition was also observed in T47D and MDA-MB-231 cells, but not in MCF12A cells. This growth inhibition was associated with G1 phase arrest; reduced cyclin D1 and D3, cyclin-dependent kinase 4 (CDK4), E2F1, and retinoblastoma protein (pRb) expression; and increased cyclin-dependent kinase inhibitor 1B (p27kip1) expression. Moreover, the SUAM-14746-mediated cell cycle arrest of MCF7 cells was associated with increased pRb2/p130 protein expression and an increase in the number of cells in the quiescent G0 state, as defined by low RNA levels.
CONCLUSIONS: SUAM-14746 inhibited breast cancer cell growth in a cytostatic manner without inducing lethality, and POP-specific inhibitors may be an effective treatment against ER+ and ER- breast cancer.

Entities:  

Keywords:  Cell cycle arrest; Human breast cancer cell lines; Prolyl oligopeptidase; Quiescent G0 state; SUAM-14746

Mesh:

Substances:

Year:  2017        PMID: 28070831     DOI: 10.1007/s12282-017-0752-5

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.

Authors:  Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V Levenson; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

2.  Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry.

Authors:  Justin M Di Trani; Stephane De Cesco; Rebecca O'Leary; Jessica Plescia; Claudia Jorge do Nascimento; Nicolas Moitessier; Anthony K Mittermaier
Journal:  Nat Commun       Date:  2018-03-01       Impact factor: 14.919

3.  Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma.

Authors:  Sarah Adriana Scuderi; Giovanna Casili; Alessia Filippone; Marika Lanza; Rossella Basilotta; Raffaella Giuffrida; Stefania Munaò; Lorenzo Colarossi; Anna Paola Capra; Emanuela Esposito; Irene Paterniti
Journal:  Oncotarget       Date:  2021-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.